1[1]Zhang ZX,Roman GC,Hong Z,et al.Parkinson's disease in China:prevalence in Beijing,Xian and Shanghai[J].Lancet,2005,365 (9459):595.
2[2]LeWitt PA,Nyholm D.New developments in levodopa therapy[J].Neurology,2004,62 (Suppl 1):9.
3[3]Jenner P,Olanow CW.Oxidative stress and the pathogenesis of Parkinson's disease[J].Neurology,1996,47 (Suppl 3):161.
4[4]Anthong HV Schapira,DSc MD,FRCP,et ad.Neuroprotection and dopamine agonists[J].Neurology,2002,58(Suppl 1):9.
5[5]Shiozaki S,Ichikawa S,Nakamura J,et al.Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP[J].Psychopharmacology,1999,147 (1):90.
6[6]Kanda T,Jackson MJ,Smith LA,et al.Combined use of the adenosine A2A antagonist KW-6002 with I-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys[J].Experimental Neurology,2000,162 (2):321.
7[7]Knoll J.(-) Deprenyl (Selegiline):past,present and future[J].Neurobiology (Bp),2000,8 (2):179.
8[8]Rabey JM,Sagi I,Huberman M,et al.Rasagiline mesylate,a new MAO-B inhibitor for the treatment of Parkinson's disease:a double-blind study as adjunctive therapy to levodopa[J].Clinical Neuropharmacology,2000,23 (6):324.
9[9]Poewe W,Deuschl G,Gordin A,et ad.The role of COMT inhibition in the treatment of Parkinson's disease[J].Neurology,2004,62 (Suppl 1):31.
10[10]Delanty N,Marc A,Dichter MD,et al.Antioxidant therapy in neurologic disease[J].Archives of Neurology,2000,57 (9):1265.
